Please login to the form below

Not currently logged in
Email:
Password:

Astellas Europe appoints Ken Jones as CEO

Ken Jones, chief operating officer of Astellas Pharma Europe, has been appointed president and CEO of the company

Ken Jones has been appointed president and CEO of Astellas Pharma Europe – the European subsidiary of Japan-based Astellas Pharma.

Jones, who leaves his role of current chief operating officer with the company, takes over from Masao Yoshida who has been appointed as president and CEO of Astellas' US division.

"I am delighted and honoured to be taking on this new role and I look forward to building on Astellas Pharma Europe's considerable achievements," said Jones. "In spite of the tough market conditions which the industry is facing, we're in a strong position and have clear strategies for growth through expanding and developing our core franchises."

These strategies include expanding the company's efforts into pain management, anti-infectives and oncology while maintaining a leading presence in transplantation and urology.

In line with these plans, Astellas has entered several partnerships recently, including a deal with Optimer Pharmaceuticals involving the development and commercialisation in Europe of clostridium difficile treatment, fidaxomicin. Astellas has also agreed a partnership deal with AVEO Pharmaceuticals to develop investigational cancer treatment, tivozanib.

Jones joined Yamanouchi as vice president, European marketing, in 2003. Yamanouchi then merged with Fujisawa to form Astellas in 2005, with Jones being promoted to senior vice president, sales, marketing and medical.

Prior to his work with Astellas, he spent 16 years with Allergan working in Europe, the US and Japan.

11th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Top Pharma News

TopPharmaNews.com is a global pharma magazine dedicated to delivering fresh news to society. The team at the TopPharmaNews.com cater non-biased,...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics